



PATENT APPLICATION

FEE AUTHORIZATION / AMENDMENT TRANSMITTAL LETTER		Attorney's Docket No: 3198	
Serial No. 09/851,673	Filing Date May 8, 2001	Examiner C. L. Smith	Group Art Unit 1631
In Re Application of Jonathan M. J. Derry, William C. Fanslow III, and William C. Dougall			
For METHODS FOR IDENTIFYING COMPOUNDS THAT ANTAGONIZE CD40 SIGNALING (as amended)			
TO THE HONORABLE COMMISSIONER FOR PATENTS:			
<input type="checkbox"/> Applicant(s) request(s) the following extension of time under 37 CFR 1.136(a):			
<input type="checkbox"/> One month of original due date (\$110.00)			
<input type="checkbox"/> Two months of original due date (\$410.00)			
<input type="checkbox"/> Three months of original due date (\$930.00)			
<input type="checkbox"/> Four months of original due date (\$1,450.00)			
<input type="checkbox"/> Five months of original due date (\$1,970.00)			
<input type="checkbox"/> A response in connection with the matter for which this extension is requested:			
<input type="checkbox"/> is filed herewith.			
<input type="checkbox"/> has been filed.			
<input type="checkbox"/> The response is the filing of a continuing prosecution application, the prior application having an express abandonment conditioned on the granting of a filing date to the continuing application.			
<input checked="" type="checkbox"/> The accompanying papers include amended claims for which no additional fee is required.			
<input type="checkbox"/> The accompanying papers include amended claims the fee for which has been calculated as follows:			

RECEIVED  
APR 22 2003  
TECH CENTER 1600/2900

## CLAIMS AS AMENDED

(1)	(2) Claims remaining After amendment	(3)	(4) Highest number Previously paid for	(5) No. of Extra claims present	(6) Rate	(7) Additional Fee
Total Claims	*15	Minus	**24 =	0	x \$18	= \$ 0.00
Indep. Claims	3	Minus	***5 =	0	x \$84	= 0.00
<input type="checkbox"/> First Appearance of a multiple dependent claim					+ \$280	= 0.00
Total Additional Fee for this Amendment						\$0.00

- \* If the entry in column 2 is less than the entry in column 4, write "0" in column 5.  
\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.  
\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.  
The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col 1. of a prior amendment or the number of claims originally filed.

☐ The following other fees are incurred by the accompanying papers.

☐ Other: \_\_\_\_\_


Please charge Deposit Account No. 09-0089 in the name of Immunex Corporation in the amount of \$ \_\_\_\_\_. A duplicate copy of this petition is attached.

☐ If an additional extension of time is required, please consider this a request therefore.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required by the accompanying papers, or credit any overpayment to Deposit Account No. 09-0089.

Please Send Future Correspondence To:


Immunex Corporation  
Law Department  
51 University Street  
Seattle, Washington 98101  
(206) 587-0430


  
Patricia Anne Perkins  
Agent for Applicants  
Registration No.: 34,693  
Phone: (206) 265-4782  
Date: April 15, 2003

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Honorable Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

April 15, 2003  
Date

  
Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Jonathan M. J. Derry, William  
C. Fanslow III and William C. Dougall

Docket No.: 3198

Group Art Unit: 1631

Examiner: Smith, C.L.

Serial No: 09/851,673

Filed: May 8, 2001

For: METHODS FOR IDENTIFYING COMPOUNDS THAT ANTAGONIZE  
CD40 SIGNALING (as amended)

Honorable Commissioner of Patents  
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION AND AMENDMENT A

Sir:

In response to the Office Action January 15, 2003, please amend the above-  
identified application as follows:

- **Introductory Comments** begin on page 2 of this paper
- **Amendments to the Specification** begin on page 3 of this paper.
- **Amendments to the Claims** are reflected in the listing of claims which begin  
on page 6 of this paper.
- **Remarks** begin on page 11 of this paper.
- **Conclusions** begin on page 19 of this paper.
- **Exhibit A**

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States  
Postal Service as first class mail in an envelope addressed to: Honorable Commissioner  
for Patents, Washington, D.C. 20231, on the date indicated below.

Signed: Elizabeth M. McCarthy  
Elizabeth M. McCarthy

Date: April 15, 2003

RECEIVED  
APR 22 2003  
TECH CENTER 1600/2900

#131A  
Plunkett  
4/24/03

**Introductory Comments**

This Response and Amendment is responsive to an Office Action having a mailing date of January 15, 2003. Claim 2 is being canceled and replaced by newly added claim 25; newly added claims 26 through 39 are also being added herein, as shown on the following pages. The specification is being amended as shown in this Response.

Applicants thank the Examiner for an opportunity to discuss this case in a telephone interview on April 11, 2003. As discussed during the telephone interview, applicants are amending the specification to correct obvious errors and render it clear to one of ordinary skill in the art. Claim 2 is being canceled and re-presented as new claim 25, which includes several changes discussed during the telephone interview (and discussed in more detail herein) to more particularly point out and distinctly claim what applicants regard as their invention. Applicants are also submitting herewith evidence that methods to identify antagonists of CD40 signaling possess utility in the eyes of those of ordinary skill in the art.